[go: up one dir, main page]

PE20081633A1 - Derivados de piridina como antagonistas del receptor p2y12 - Google Patents

Derivados de piridina como antagonistas del receptor p2y12

Info

Publication number
PE20081633A1
PE20081633A1 PE2008000130A PE2008000130A PE20081633A1 PE 20081633 A1 PE20081633 A1 PE 20081633A1 PE 2008000130 A PE2008000130 A PE 2008000130A PE 2008000130 A PE2008000130 A PE 2008000130A PE 20081633 A1 PE20081633 A1 PE 20081633A1
Authority
PE
Peru
Prior art keywords
alkyl
carbamoil
hydroxyalkyl
cycloalkyl
halogen
Prior art date
Application number
PE2008000130A
Other languages
English (en)
Inventor
Thomas Antosson
Ruth Bylund
Johan Johansson
Peter Bach
David Brown
Fabrizio Giordanetto
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39608896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081633(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20081633A1 publication Critical patent/PE20081633A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRIDINA DE FORMULA (I) DONDE R1 ES R6OC(O), R7C(O), ENTRE OTROS, DONDE R6 ES ALQUILO(C1-C12), CICLOALQUILO(C3-C6), HIDROXIALQUILO(C2-C12), ENTRE OTROS; R7 ES ALQUILO(C1-C12), HIDROXIALQUILO(C1-C12), ENTRE OTROS; R2 ES CN, HALOGENO, ALQUILO(C4-C8), ALCOXI(C1-C12), ENTRE OTROS; R4 ES H, CN, HALOGENO, ALQUILO(C1-C12), ENTRE OTROS; R14 ES H, OH, ALQUILO(C1-C8), CICLOALQUILO(C3-C6), ENTRE OTROS; R15 ES H, ARILO, HALOGENO, HIDROXIALQUILO(C1-C12), ENTRE OTROS; Rc ES UN ENLACE DIRECTO, ALQUILENO(C1-C4), ALQUILENOXI(C1-C4), ENTRE OTROS; Rd ES ALQUILO(C1-C12), CICLOALQUILO(C3-C8), ARILO, ENTRE OTROS; X ES UN ENLACE SIMPLE, IMINO, METILENO, IMINOMETILENO, ENTRE OTROS; B ES UN ANILLO MONOCICLICO O BICICLICO DE 4 A 11 MIEMBROS QUE COMPRENDE UNO O MAS NITROGENOS, Y OPCIONALMENTE O U S. SON COMPUESTOS PREFERIDOS: 6-{4-[(BENCILSULFONIL)CARBAMOIL]PIPERIDIN-1-IL}-5-CIANO-2-METOXINICOTINATO DE ETILO, 6-{3-[(BENCILSULFONIL)CARBAMOIL]AZETIDIN-1-IL}-5-CIANO-2-METOXINICOTINATO DE ETILO, 6-{4-[(BENCILSULFONIL)CARBAMOIL]PIPERIDIN-1-IL}-5-CIANO-2-ETOXINICOTINATO DE ETILO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR P2Y12 SIENDO UTILES EN EL TRATAMIENTO DE LA AGREGACION PLAQUETARIA, ANGINA INESTABLE, INFARTO DE MIOCARDIO, COMPLICACIONES TROMBOTICAS ARTERIALES PRIMARIAS DE LA ATEROSCLEROSIS
PE2008000130A 2007-01-12 2008-01-11 Derivados de piridina como antagonistas del receptor p2y12 PE20081633A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88465807P 2007-01-12 2007-01-12

Publications (1)

Publication Number Publication Date
PE20081633A1 true PE20081633A1 (es) 2009-01-18

Family

ID=39608896

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000130A PE20081633A1 (es) 2007-01-12 2008-01-11 Derivados de piridina como antagonistas del receptor p2y12

Country Status (18)

Country Link
US (2) US20080171732A1 (es)
EP (1) EP2111400A4 (es)
JP (1) JP2010515728A (es)
KR (1) KR20090096742A (es)
AR (1) AR064866A1 (es)
AU (1) AU2008203953A1 (es)
BR (1) BRPI0806529A2 (es)
CA (1) CA2674998A1 (es)
CL (1) CL2008000091A1 (es)
CO (1) CO6190618A2 (es)
EC (1) ECSP099481A (es)
IL (1) IL199439A0 (es)
MX (1) MX2009007429A (es)
PE (1) PE20081633A1 (es)
RU (1) RU2009123928A (es)
TW (1) TW200833335A (es)
UY (1) UY30866A1 (es)
WO (1) WO2008085117A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506193A (zh) * 2006-07-04 2009-08-12 阿斯利康(瑞典)有限公司 新吡啶类似物
AR072697A1 (es) * 2008-07-07 2010-09-15 Astrazeneca Ab Compuestos de piridina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastorno de agregacion plaquetaria
JP2014051434A (ja) * 2010-12-28 2014-03-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
RU2602456C1 (ru) * 2015-10-20 2016-11-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ оценки активности ароматазы овариальных фолликулов
WO2017153235A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
ES2877571T3 (es) 2016-07-19 2021-11-17 Bayer Cropscience Ag Derivados de heterociclos bicíclicos condensados como pesticidas
TW202415651A (zh) 2022-07-29 2024-04-16 日商住友製藥股份有限公司 含氮飽和雜環衍生物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
ATE309999T1 (de) * 2000-02-04 2005-12-15 Portola Pharm Inc Blutplättchen-adp-rezeptor-inhibitoren
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) * 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
JP3500429B2 (ja) * 2000-11-01 2004-02-23 現代自動車株式会社 ポリプロピレン樹脂組成物
FR2820057A1 (fr) * 2001-01-30 2002-08-02 Ct De Transfert De Technologie Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
KR20070032648A (ko) * 2004-05-12 2007-03-22 브리스톨-마이어스 스큅 컴퍼니 혈전 상태의 치료에 유용한 ｐ２ｙ１ 수용체의 우레아길항제
WO2006012226A2 (en) * 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
AU2005294378A1 (en) * 2004-10-04 2006-04-20 Mount Sinai Hospital Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus
BRPI0606437A (pt) * 2005-01-06 2008-03-11 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta
WO2007008140A1 (en) * 2005-07-13 2007-01-18 Astrazeneca Ab New pyridine analogues
JP2009542643A (ja) * 2006-07-04 2009-12-03 アストラゼネカ アクチボラグ 新規ピリジン類似体
CN101511815A (zh) * 2006-07-04 2009-08-19 阿斯利康(瑞典)有限公司 新型吡啶类似物
CN101506193A (zh) * 2006-07-04 2009-08-12 阿斯利康(瑞典)有限公司 新吡啶类似物

Also Published As

Publication number Publication date
CA2674998A1 (en) 2008-07-17
TW200833335A (en) 2008-08-16
US20100137277A1 (en) 2010-06-03
WO2008085117A1 (en) 2008-07-17
CO6190618A2 (es) 2010-08-19
AR064866A1 (es) 2009-04-29
EP2111400A1 (en) 2009-10-28
JP2010515728A (ja) 2010-05-13
MX2009007429A (es) 2009-07-17
ECSP099481A (es) 2009-08-28
US20080171732A1 (en) 2008-07-17
KR20090096742A (ko) 2009-09-14
RU2009123928A (ru) 2011-02-20
BRPI0806529A2 (pt) 2014-04-22
UY30866A1 (es) 2008-09-02
AU2008203953A1 (en) 2008-07-17
EP2111400A4 (en) 2010-07-07
CL2008000091A1 (es) 2008-09-05
IL199439A0 (en) 2010-03-28

Similar Documents

Publication Publication Date Title
PE20081633A1 (es) Derivados de piridina como antagonistas del receptor p2y12
PE20090621A1 (es) Pirrolidina-aril-eteres como antagonistas de receptores de nk3
PE20110574A1 (es) Derivados de fenilamida y de piridilamida como agonistas de gpbar1
PE20130184A1 (es) Compuesto heterociclico
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20071116A1 (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
PE20141681A1 (es) Inhibidores de btk
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
PE20091039A1 (es) IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10
PE20070585A1 (es) Derivados de sulfonamida como activadores de glucoquinasa
ES2297727T3 (es) Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos.
AR049784A1 (es) Derivados sustituidos de morfolina y tiomorfolina
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20091035A1 (es) Derivados de 2-aminopirimidina
ATE475645T1 (de) Pyrrolidinderivate als doppelte nk1/nk3- rezeptorenantagonisten
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20091268A1 (es) Derivados heterociclicos como inhibidores de pi3 quinasa
DE602005023963D1 (de) Weitere heteropolycyclische verbindungen und deren verwendung als antagonisten des metabotropen glutamatrezeptors
PE20141169A1 (es) Derivados de etinilo
PE20131100A1 (es) Combinacion del compuesto glyt1 con antipsicoticos
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
PE20070141A1 (es) Derivados de isoquinolina como inhibidores de rho-cinasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed